Arthur Higgins - Ecolab Independent Director

ECL Stock  USD 247.70  0.32  0.13%   

Director

Mr. Arthur J. Higgins serves as an Independent Director of Ecolab Inc. He served as President and Chief Executive Officer and member of the Board of Directors of Depomed Inc., a specialty pharmaceutical company. Director of Ecolab since 2010. Vice Chair of the Safety, Health and Environment Committee and member of the Compensation Committee. Prior to joining Depomed in March 2017, Mr. Higgins was a Senior Advisor to Blackstone Healthcare Partners, the dedicated healthcare team of The Blackstone Group, from May 2010 to March 2017. Prior to joining Assertio Therapeutics in March 2017, Mr. Higgins served as Senior Advisor to Blackstone Healthcare Partners, the dedicated healthcare team of The Blackstone Group from May 2010 to March 2017. He previously served at Bayer HealthCare AG as Chairman of the Board of Management from January 2006 to May 2010 and Chairman of the Executive Committee from July 2004 to May 2010. Prior to that time, Mr. Higgins held the offices of Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 until 2004. Prior to joining Enzon Pharmaceuticals, Mr. Higgins spent 14 years with Abbott Laboratories, holding several executive leadership positions, including serving as President of the Pharmaceutical Products Division from 1998 to 2001. He is a past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America, of the Council of the International Federation of Pharmaceutical Manufacturers and Associations and President of the European Federation of Pharmaceutical Industries and Associations . since 2010.
Age 64
Tenure 14 years
Address 1 Ecolab Place, Saint Paul, MN, United States, 55102-2233
Phone800 232 6522
Webhttps://www.ecolab.com
Higgins joined The Blackstone Group in 2010. Prior to that Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG, a developer and manufacturer of human and animal health products, and Chairman of the Bayer HealthCare Executive Committee. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to joining Enzon Pharmaceuticals, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is a past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America, of the Council of the International Federation of Pharmaceutical Manufacturers and Associations and President of the European Federation of Pharmaceutical Industries and Associations .

Arthur Higgins Latest Insider Activity

Tracking and analyzing the buying and selling activities of Arthur Higgins against Ecolab stock is an integral part of due diligence when investing in Ecolab. Arthur Higgins insider activity provides valuable insight into whether Ecolab is net buyers or sellers over its current business cycle. Note, Ecolab insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ecolab'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Ecolab Management Efficiency

The company has Return on Asset of 0.0742 % which means that on every $100 spent on assets, it made $0.0742 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2516 %, implying that it generated $0.2516 on every 100 dollars invested. Ecolab's management efficiency ratios could be used to measure how well Ecolab manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to rise to 0.18 this year, although the value of Return On Tangible Assets will most likely fall to 0.09. At this time, Ecolab's Asset Turnover is quite stable compared to the past year.
Ecolab Inc has 8.73 B in debt with debt to equity (D/E) ratio of 1.26, which is OK given its current industry classification. Ecolab Inc has a current ratio of 1.32, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for Ecolab to invest in growth at high rates of return.

Similar Executives

Showing other executives

DIRECTOR Age

Ramaswami SeshasayeeQuaker Chemical
72
Ian AshkenElement Solutions
60
EllenBlair ChubeOil Dri
39
John RodenH B Fuller
70
George RoethOil Dri
59
Daniel FlornessH B Fuller
57
Paul HindsleyOil Dri
61
Michael NemeroffOil Dri
57
Melissa McClainQuaker Chemical
N/A
Dante ParriniH B Fuller
56
Maria HiladoH B Fuller
56
Leslie GarberOil Dri
N/A
Thomas HandleyH B Fuller
66
Ruth KimmelshueH B Fuller
58
Steven WilliamsInnospec
68
John CarmolaMinerals Technologies
65
Nichelle MaynardElliottElement Solutions
51
E ONealElement Solutions
69
Michael GossElement Solutions
60
Marc RobinsonMinerals Technologies
59
Mark DouglasQuaker Chemical
58
Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company was founded in 1923 and is headquartered in Saint Paul, Minnesota. Ecolab operates under Specialty Chemicals classification in the United States and is traded on New York Stock Exchange. It employs 47000 people. Ecolab Inc (ECL) is traded on New York Stock Exchange in USA. It is located in 1 Ecolab Place, Saint Paul, MN, United States, 55102-2233 and employs 48,000 people. Ecolab is listed under Specialty Chemicals category by Fama And French industry classification.

Management Performance

Ecolab Inc Leadership Team

Elected by the shareholders, the Ecolab's board of directors comprises two types of representatives: Ecolab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ecolab. The board's role is to monitor Ecolab's management team and ensure that shareholders' interests are well served. Ecolab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ecolab's outside directors are responsible for providing unbiased perspectives on the board's policies.
Joanne Mullen, Senior Officer
Jandeen Boone, General VP
Arthur Higgins, Independent Director
Shari Ballard, Independent Director
Michael McCormick, Executive Vice President General Counsel, Secretary
Michael Larson, Independent Director
Daniel Schmechel, Chief Financial Officer, Treasurer
Larry Berger, Executive Vice President Chief Technical Officer
Jennifer Bradway, Senior Vice President Chief Accounting Officer, Corporate Controller
Roberto Inchaustegui, Executive Vice President and Presidentident – Global Services and Specialty
David MacLennan, Independent Director
Douglas Baker, Chairman, CEO and Member of Safety, Health and Environment Committee
Elizabeth Simermeyer, Executive Vice President and Presidentident – Global Healthcare and Life Sciences
Deric Bryant, Executive Vice President and Presidentident – Upstream Energy
Suzanne Vautrinot, Independent Director
Andrew Hedberg, Director Relations
John Zillmer, Independent Director
Angela Busch, Executive Vice President - Corporate Strategy and Business Development
Lionel Nowell, Independent Director
Christophe Beck, Executive Vice President and Presidentident, Regions
Alexander Boo, Executive Vice President and President – Global Markets
Laurie Marsh, Executive Vice President - Human Resources
Darrell Brown, Executive Vice President and President – Energy Services
Jeffrey Ettinger, Lead Independent Director
Timothy Mulhere, Executive Vice President and President – Global Institutional & Specialty Services
David Bingenheimer, Executive Officer
Jill Wyant, Executive Vice President and Presidentident - Global Food & Beverage
Gail Peterson, Senior Vice President - Global Marketing and Communications
Jerome Charton, Executive Vice President and President – Global Regions
Victoria Reich, Independent Director
Scott Kirkland, Senior Vice President Principal Accounting Officer, Corporate Controller
Barbara Beck, Independent Director
Machiel Duijser, Executive Vice President Chief Supply Chain Officer
Lanesha Minnix, General VP
Tracy McKibben, Independent Director

Ecolab Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ecolab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ecolab Inc is a strong investment it is important to analyze Ecolab's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ecolab's future performance. For an informed investment choice regarding Ecolab Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ecolab Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ecolab. If investors know Ecolab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ecolab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.065
Dividend Share
2.28
Earnings Share
7.13
Revenue Per Share
55.042
Quarterly Revenue Growth
0.178
The market value of Ecolab Inc is measured differently than its book value, which is the value of Ecolab that is recorded on the company's balance sheet. Investors also form their own opinion of Ecolab's value that differs from its market value or its book value, called intrinsic value, which is Ecolab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ecolab's market value can be influenced by many factors that don't directly affect Ecolab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ecolab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ecolab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ecolab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.